Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jul 4;8(1):10101.
doi: 10.1038/s41598-018-28268-2.

The prognostic significance of metabolic syndrome and weight loss in esophageal squamous cell carcinoma

Bowen Liu  1 , Bo Cheng  2 , Cong Wang  1 , Pengxiang Chen  1 , Yufeng Cheng  3
Affiliations

The prognostic significance of metabolic syndrome and weight loss in esophageal squamous cell carcinoma

Bowen Liu et al. Sci Rep. .

Abstract

Our study aimed to investigate the association between metabolic syndrome and postoperative survival in patients with esophageal squamous cell carcinoma, and evaluate whether metabolic syndrome can predict the prognosis in esophageal cancer patients. The retrospective study reviewed 519 patients with esophageal squamous cell carcinoma who had received esophagetomy and lymphnode dissections in the Department of Thoracic Surgery, Qilu Hospital of Shandong University between January 2007 and December 2011. All patients were followed up until December 2016. The median follow-up time was 39.59 months (range 0.25-72 months). The 3-year and 5-year survival rate was 51.4% and 37.0%, respectively. Kaplan-Meier survival analysis revealed a significant correlation between OS and obesity (P = 0.000), weight loss (P = 0.000), diabetes (P = 0.001) and dyslipidemia (P = 0.030). Multivariate analysis indicated that advanced TNM staging (P = 0.007, HR: 1.760, 95% CI: 1.167-2.654) and more weight loss (P = 0.000, HR: 1.961, 95% CI: 1.697-2.267) were independent factors for adverse prognosis of esophageal squamous carcinoma patients. In contrast, diabetes was a protective factor in the prognosis of patients with esophageal cancer (P = 0.018, HR: 0.668, 95% CI: 0.478-0.933). Our findings suggest that TNM staging, weight changes and diabetes were independent predictors for the prognosis of esophageal cancer patients.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Kaplan-Meier analysis for overall survival (OS) and progression-free survival (PFS) of esophageal squamous cell carcinoma patients according to metabolic syndrome components, including obesity, weight loss, diabetes and dyslipidemia.
Figure 2
Figure 2
The association between obesity, weight loss, diabetes, dyslipidemia and 1-year, 3-years survival in esophageal cancer patients.
Figure 3
Figure 3
The effects of MS on survival in different subgroups. The effects of obesity, weight loss, diabetes and dyslipidemia on survival in different level of lymph node metastases (N0 vs N1–3) (A,B).The effects of obesity, weight loss, diabetes and dyslipidemia on survival in different TNM stages (TNM I stage vs TNM II-III stage) (C,D).
Figure 4
Figure 4
Kaplan–Meier analysis for the effects of obesity, weight loss, diabetes and dyslipidemia on survival in different gender categories (male vs female).
See this image and copyright information in PMC

References

    1. Chen W, et al. Cancer statistics in China, 2015. CA: a cancer journal for clinicians. 2016;66:115–132. - PubMed
    1. Jemal A, et al. Global cancer statistics. CA: a cancer journal for clinicians. 2011;61:69–90. - PubMed
    1. Torre LA, et al. Global cancer statistics, 2012. CA: a cancer journal for clinicians. 2015;65:87–108. - PubMed
    1. Rustgi AK, El-Serag HB. Esophageal carcinoma. The New England journal of medicine. 2014;371:2499–2509. doi: 10.1056/NEJMra1314530. - DOI - PubMed
    1. Koshy M, Esiashvilli N, Landry JC, Thomas CR, Jr., Matthews RH. Multiple management modalities in esophageal cancer: combined modality management approaches. The oncologist. 2004;9:147–159. doi: 10.1634/theoncologist.9-2-147. - DOI - PubMed

Publication types